An open label, single arm, prospective clinical study to evaluate the safety of CUQ1720P(curcumagalactomannoside) in healthy subjects.

Akay Flavours and Aromatics Private Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Subjects having weight > 50 Kg
•2.Subjects who have no evidence of any underlying disease
•3.Women of child bearing potential practicing an acceptable method of birth control as judged by the investigator(s) [such as condoms, foams, jellies, diaphragm, intrauterine device, oral or long acting injected contraceptives] from at least 2 months prior to study entry and through the duration of the study; or postmenopausal for at least 1 year, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy has been performed on the subject); with a negative urine pregnancy test.
•4. Must be willing and able to give informed consent and comply with the study procedures

•1Subjects suffering from any chronic health conditions (e.g. diabetes, hypertension, chronic renal failure, heart, thyroid and liver disease) requiring medical treatment
•2History of Chronic metabolic disease, Psychiatric illness,Drug abuse, smoking, abuse/addiction to alcohol,Eating disorder such as bulimia or binge eating,Endocrine abnormalities including stable thyroid disease, Cardiovascular surgery / History of any major surgery
•3Subjects allergic to herbal products
•4Known HIV or Hepatitis B positive or any other immuno-compromised state
•5Diagnosis of any other clinically significant medical condition which in opinion of investigator may jeopardize subjectâ??s safety and preclude trial participation
•6Currently participating or having participated in another clinical trial during the last 1 month prior to the beginning of this study
•7.Any additional condition(s) that in the Investigators opinion would warrant exclusion from the study or prevent the subject from completing the study

发起方

Akay Flavours and Aromatics Private Limited